IXICO plc Directorate Change (6728J)
August 22 2019 - 2:02AM
UK Regulatory
TIDMIXI
RNS Number : 6728J
IXICO plc
22 August 2019
22(nd) August 2019
IXICO plc
("IXICO" or the "Company")
Directorate changes
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, today announces two directorate
changes.
As anticipated, Grant Nash, who was appointed as CFO on 29 April
2019, will join the board with immediate effect. In his executive
director role, Grant leads the Company's Finance, Legal and IT
functions. Grant joined IXICO from UK Biobank, a national and
international health research data resource, where he had been
Finance Director since 2014.
Tim Sharpington, who has served as non-executive director and
senior independent director since October 2013, has informed the
Company of his intention to step down from the board at the end of
the current financial year to focus on his executive
responsibilities elsewhere. His responsibilities as IXICO's senior
independent director and chair of the remuneration committee will
be assumed by Mark Warne, currently a non-executive director.
Following the directorate changes the Company will have two
executive directors and three independent non-executive
directors.
Giulio Cerroni, Chief Executive Officer of IXICO, commented:
"Grant's appointment to the board reflects the substantial
contribution he has already made to IXICO since his appointment as
CFO on 29(th) April 2019. He has brought strong financial
leadership skills combined with a deep appreciation of operational
excellence at a time of significant revenue growth and an
accelerated path to profitability. Separately, I would like to
thank Tim for all his counsel and guidance to me personally since I
joined the company and wish him well for the future."
Charles Spicer, Chairman of IXICO, commented: "On behalf of the
board and personally, I would like to thank Tim warmly for his many
years of service to the Company and the board. Since its admission
to AIM in 2013, he has guided and supported IXICO through a number
of strategic challenges and changes. In that time, the Company has
significantly enhanced its position in providing specialist data
analytics for neuroscience drug development and more than doubled
revenues over the last three years. We all wish him well for his
future endeavours."
Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Grant
Robert Nash (aged 42) has held the following directorships or
partnerships in the past five years:
Current Previous
The Leach Fourteenth None
Trust
Golden Bay Mansions
Limited
---------
Mr Nash does not currently hold any shares in the Company.
There is no further information required to be disclosed in
respect of the above appointment pursuant to Rule 17 and Schedule 2
(g) of the AIM Rules for Companies.
For further information please contact:
IXICO plc +44 (0) 20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0) 20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Optimum Strategic Communications +44 (0) 203 950 9144
Mary Clark / Anne Marieke Ezendam / Supriya
Mathur
IXICO@optimumcomms.com
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
mission is to transform the progression of our biopharmaceutical
clients' neurological therapeutic pipelines through the application
of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global
biopharmaceutical industry to interpret data from brain scans and
digital biosensors to enable better trial design, site
qualification, patient selection and clinical outcomes. We provide
technology-enabled services across all phases of clinical
evaluation. Our integrated digital platform provides a scalable and
secure infrastructure for the capture and analysis of regulatory
compliant clinical data to enable clients to make rapid, better
informed decisions. IXICO is also collaborating with partners to
develop new analytical techniques and companion digital health
products targeted at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAMMGZRFGNGLZM
(END) Dow Jones Newswires
August 22, 2019 02:02 ET (06:02 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024